Employee Incentive Program: Annexon has granted 19,000 stock options to a new non-executive employee under the 2022 Employment Inducement Award Plan, with an exercise price of $4.91 per share, reflecting the company's commitment to attracting and retaining talent.
Long-Term Incentive Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, designed to enhance employee retention and motivation through a long-term incentive mechanism.
Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations while strengthening its position in attracting and retaining key talent in the competitive biopharmaceutical sector.
Strategic Development Focus: Annexon is focused on developing complement inhibitors targeting neuroinflammation to address unmet medical needs for nearly 10 million people globally, and this incentive measure will help attract more professionals to advance its research and development efforts.
ANNX
$4.9+Infinity%1D
Analyst Views on ANNX
Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.00 USD with a low forecast of 8.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.800
Low
8.00
Averages
14.00
High
27.00
Current: 4.800
Low
8.00
Averages
14.00
High
27.00
Wells Fargo
NULL
to
Overweight
upgrade
$14 -> $27
2025-11-19
Reason
Wells Fargo
Price Target
$14 -> $27
2025-11-19
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Annexon to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument's Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.
BofA
Buy
downgrade
$9 -> $8
2025-11-16
Reason
BofA
Price Target
$9 -> $8
2025-11-16
downgrade
Buy
Reason
BofA lowered the firm's price target on Annexon to $8 from $9 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
Wells Fargo
Derek Archila
Overweight
maintain
$14
2025-07-10
Reason
Wells Fargo
Derek Archila
Price Target
$14
2025-07-10
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila spoke to Annexon as the shares traded down earlier today post the circulation of a tweet from a month ago by a physician. A doctor claimed the FDA requested a confirmatory study of tanruprubart in the U.S. as it did not accept the comparison to the International GBS Outcomes Study database as evidence of efficacy in western Guillain-Barre syndrome, the analyst tells investors in a research note. Wells spoke to management, who said the post is not factual. Annexon's CEO noted this post was one week before the company's FDA meeting, Wells points out. The company told the firm that the FDA has not requested another confirmatory trial. After selling off earlier in the day, shares of Annexon are up 2% to $2.82 in afternoon trading. Wells keeps an Overweight rating on the shares with a $14 price target. It recommends buying the shares on weakness.
H.C. Wainwright
Buy
downgrade
$20 -> $14
2025-05-13
Reason
H.C. Wainwright
Price Target
$20 -> $14
2025-05-13
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annexon to $14 from $20 and keeps a Buy rating on the shares. The firm reduced the stock's multiple and increased its discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. Annexon announced that it is on track to meet with the FDA for tanruprubart around Q2, the analyst tells investors in a research note.
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
